CommercialCoverageMedium impact
07.07.09j, Stem-Cell Therapy/Platelet-Rich Plasma for Orthopedic Applications and Platelet-Rich Plasma/Platelet-Derived Growth Factor for Wound Healing and Other Miscellaneous Non-Orthopedic Conditions
Independence Blue Cross·Orthopedics, Wound Care, General Surgery·Medical Policy
Effective date
Jan 6, 2025
We identified it
Jun 19, 2026
Summary
This recent policy (effective 01/06/2025) updates coverage and reimbursement guidelines for stem-cell therapy, platelet-rich plasma (PRP) for orthopedic applications, and PRP/platelet-derived growth factor (PDGF) for wound healing and non-orthopedic conditions. The billing team must review the full policy text to identify specific coverage determinations, prior authorization requirements, and applicable billing codes that may have changed.
Action Required
By 01/13/2025: Billing team must obtain and review the complete policy text from https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=01&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#commercial-07-07-09j to identify: (1) specific CPT/HCPCS codes affected, (2) new prior authorization requirements, (3) covered vs. non-covered indications, and (4) any documentation requirements. Update billing system rules, encounter forms, and provider guidelines accordingly. Flag any stem-cell therapy or PRP procedure claims submitted after 01/06/2025 for compliance verification. Contact the payer directly if specific billing codes are not clearly stated in the policy summary.